AUS
NZ
UK
CA
USA
IND
Healthcare
Stock Market Spotlight: Breakthrough in Wound Care as (ASX:ARX) Advances Trial
March 30, 2026 07:14 PM AEDT| By SamAroa Biosurgery advances wound care innovation with Symphony trial completion, showcasing improved healing outcomes and strengthening its clinical and commercial outlook in global healthcare markets.
Market Watch ASX 100 Highlights Key Sector Activity
March 30, 2026 03:57 PM AEDT| By SamASX 100 reflects sector-wide activity with CSL and key industries contributing to diversified market participation within the All Ordinaries framework.
Blinklab ASX 300 Healthcare Operations and ASX Ordinaries Stocks
March 29, 2026 04:33 AM AEDT| By SamBlinklab healthcare operations focus on digital neurological screening systems and structured resource allocation within the ASX healthcare ecosystem and broader market framework.
Telix Pharmaceuticals Update Sparks ASX Healthcare Momentum Shift
March 29, 2026 04:31 AM AEDT| By SamTelix Pharmaceuticals update highlights growing momentum in ASX healthcare sector as regulatory progress and innovation strengthen biotechnology outlook across Australian market landscape and investor attention expands steadily.
Unlock PME Valuation Signals Ahead of ASX 200 Momentum
March 29, 2026 04:27 AM AEDT| By Team Kalkine MediaPME reflects healthcare imaging strength, institutional integration, and digital transformation themes influencing Australian equities, structured valuation analysis, and long-term healthcare technology positioning across markets.
Healthcare Innovator 4DMedical in ASX 300 Gains Attention
March 29, 2026 04:24 AM AEDT| By Team Kalkine Media4DMedical advances respiratory imaging technology while strengthening operations through a major capital raise, supporting global expansion and healthcare innovation within the ASX 300 landscape.
4DMedical Rallies as Expansion Story Gains Traction
March 27, 2026 09:05 PM AEDT| By Sam4DMedical re-enters focus after a capital raise, with its imaging innovation and expansion strategy shaping valuation discussions and market sentiment.
ResMed & Netwealth: A Fresh Look at Valuation Trends
March 27, 2026 07:54 PM AEDT| By SamResMed and Netwealth shares are drawing attention as valuation metrics shift below historical trends, offering insights into business resilience and evolving market dynamics.
Lumos Diagnostics Gains FDA Nod to Expand US Reach
March 27, 2026 05:20 PM AEDT| By SamLumos Diagnostics advances US expansion after regulatory clearance, enabling wider clinical adoption of its rapid test and supporting growth through strategic funding and operational scale-up.
Sigma Healthcare (ASX:SIG) Navigates Post-Merger Shifts Amid ASX Healthcare Trends
March 27, 2026 03:53 PM AEDT| By SamSigma Healthcare (ASX:SIG) navigates post-merger corrections while leveraging Chemist Warehouse integration and stable Australian healthcare demand, offering defensive growth for global investors.
Is 4DMedical (ASX:4DX) expanding imaging adoption?
March 27, 2026 03:42 PM AEDT| By Sam4DMedical advances respiratory imaging technology, highlighting healthcare innovation and clinical integration within the ASX All Ordinaries sector.
Top 2 ASX Healthcare Sector Shows Broad Weakness
March 27, 2026 03:21 PM AEDT| By SamHealthcare stocks reflect sector-wide movement within the ASX 200, highlighting the role of large-cap companies in shaping market participation.
ASX All Ordinaries Updates: Racura Study Focus
March 27, 2026 03:02 PM AEDT| By SamRacura advances cancer research through MYC-focused studies and academic collaboration, highlighting biotechnology innovation within the ASX All Ordinaries healthcare sector.
Mesoblast (ASX:MSB; Nasdaq:MESO) Sets Stage for R&D Day as Ryoncil® Gains Commercial Traction
March 27, 2026 02:30 PM AEDT| By Team Kalkine MediaHighlights,Mesoblast has scheduled its inaugural R&D Day on 8 April 2026 in New York City.,The company reported H1 FY2026 revenue of US$51.3 million, driven by Ryoncil® launch.,Ryoncil® achieved gross sales of US$57.0 million following U.S. commercia...
ASX All Ords Healthcare Update: Lumos Diagnostics FDA Clearance
March 27, 2026 12:11 PM AEDT| By SamtaLumos Diagnostics expands healthcare diagnostics footprint through FDA CLIA waiver for FebriDx, enabling broader access to rapid infection testing across diverse clinical environments.
Radiopharm All Ordinaries Clinical Trial Milestone Update
March 27, 2026 11:29 AM AEDT| By SamRadiopharm advances clinical development with first patient dosing of its RAD compound, reflecting ongoing healthcare sector activity within the All Ordinaries framework.
Lumos Capital Move Sparks Market Attention
March 27, 2026 11:23 AM AEDT| By SamLumos Diagnostics’ capital expansion highlights evolving market dynamics, improved liquidity potential, and strategic positioning within Australia’s healthcare diagnostics sector.
CSL & Pro Medicus: Healthcare Stocks in Focus Now
March 26, 2026 06:29 PM AEDT| By SamAn in-depth look at CSL and Pro Medicus, highlighting business models, valuation insights, and their growing importance in Australia’s healthcare-driven market landscape.
Micro-X Cash Strategy in Focus Amid Growth Push
March 26, 2026 05:34 PM AEDT| By SamAn in-depth look at Micro-X’s cash flow trends, growth trajectory, and funding outlook, exploring how financial strategy aligns with broader movements across the Australian equities landscape.
Pro Medicus Journey Gains Focus Within ASX 200 Healthcare Space
March 26, 2026 04:31 PM AEDT| By SamA healthcare technology firm within the Australian market has drawn attention due to notable valuation movement, driven by imaging software adoption, global contracts, and its presence in major ASX indices.
Advertise your brand on Kalkine Media